行情

ITCI

ITCI

INTRA CELLULAR
NASDAQ

实时行情|Nasdaq Last Sale

9.48
+0.49
+5.45%
盘后: 9.48 0 0.00% 16:06 11/21 EST
开盘
9.02
昨收
8.99
最高
9.56
最低
8.75
成交量
123.77万
成交额
--
52周最高
16.76
52周最低
6.75
市值
5.24亿
市盈率(TTM)
-3.5284
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ITCI 新闻

  • 特朗普签署权宜支出法案以避免政府停摆
  • 新浪财经.1小时前
  • 罗斯百货Q3销售额同比增8% 维持Q4 EPS指引
  • 新浪财经综合.2小时前
  • 隔夜要闻:美股连续三天下跌 油价触及两个月高点
  • 新浪美股.2小时前
  • 特朗普称将在2020年大选投票前公布财务记录
  • 新华网.3小时前

更多

所属板块

生物技术和医学研究
-0.31%
制药与医学研究
+0.32%

热门股票

名称
价格
涨跌幅

ITCI 简况

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
展开

Webull提供Intra-Cellular Therapies Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。